Use of long overlapping peptides for cancer vaccine and Treg control for potentiating immune response

我们对NY-ESO-1癌症疫苗进行了I期临床试验，该疫苗使用20-mer NY-ESO-1f长肽和4种不同的30-32-mer NY-ESO-1重叠肽与匹比班尼（picbanil） k -432和Montanide ISA-51。两种疫苗的耐受性都很好。免疫监测分析显示，接种疫苗的患者均可诱导抗体、CD4和cd8t细胞反应。研究结果表明，这两种长肽疫苗都有希望用于免疫治疗。

We conducted a phase I clinical trials of NY-ESO-1 cancer vaccines using a 20-mer NY-ESO-1f long peptide and 4 different 30-32-mer NY-ESO-1 overlapping peptides with Picibanil OK-432 and Montanide ISA-51. Either vaccine was well tolerated. Immunomonitoring analysis revealed that either vaccine induced antibody, CD4 and CD8T-cell responses in the vaccinated patients. The findings indicated the either long peptide vaccine is promising for immunotherapy.